epirubicin / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

22 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
epirubicin / Generic mfg.
RC48-C024, CTR20231476: A randomized, open-label, multicenter phase II clinical study evaluating the efficacy and safety of vedicitumab alone or in combination with toripalimab or sequential chemotherapy in patients with HR-negative, HER2-low breast cancer

Ongoing
2
China
Aidixi (disitamab vedotin) - Rongchang Pharma, Pfizer, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci, carboplatin - Generic mfg., epirubicin - Generic mfg., cyclophosphamide - Generic mfg.
Remegen Biopharmaceutical (Yantai) Co., Ltd
HR-negative, HER2-low breast cancer
 
 
2012-004489-17: Clinical study for elderly or unfit for a 3-weekly chemotherapy regimen women, with early breast cancer, to evaluate the efficacy of weekly nab-paclitaxel (Abraxane®) treatment versus weekly epirubicin standard treatment. Studio clinico per donne anziane o non candidate ad assumere trattamento chemioterapico trisettimanale, operate di tumore mammario, che confronta la efficacia di un trattamento settimanale con nab-paclitaxel (Abraxane®) verso trattamento settimanale standard con epirubicina.

Ongoing
2
330
Europe
, Concentrate for solution for infusion, ABRAXANE, Epirubicina
ISTITUTO EUROPEO DI ONCOLOGIA, Celgene, Veronesi Foundation
early breast cancer in elderly patients or patients who are unfit for a polychemotherapy regimen, early breast cancer in elderly patients or patients who are unfit for a polychemotherapy regimen, Diseases [C] - Cancer [C04]
 
 
2008-003064-19: Phase-IIb-Study to Evaluate the Effect of a Neoadjuvant Chemotherapy with Docetaxel, Epirubicine and Cyclphosphamide (TEC) in Patients with primary HER-2 neu Negative Mammacarcinoma Phase-IIb-Studie zur Erfassung der Effektivität einer neoadjuvanten Chemotherapie mit Docetaxel, Epirubicin und Cyclophosphamid (TEC) bei Patientinnen mit primärem HER- 2 neu negativem Mammakarzinom Phase-IIb-Studie zur Erfassung der Effektivität einer neoadjuvanten Chemotherapie mit Docetaxel, Epirubicin und Cyclophosphamid (TEC) bei Patientinnen mit primärem HER- 2 neu negativem Mammakarzinom

Ongoing
2
150
Europe
Epirubicin, Docetaxel, Cyclophosphamid,
Universität Leipzig, Sanofi-Aventis, Amgen
Primary mamma carcinoma Brustkrebs
 
 
PETREMAC, NCT02624973: PErsonalized TREatment of High-risk MAmmary Cancer - the Trial

Active, not recruiting
2
200
Europe
Neoadjuvant tamoxifen + goserelin (premenopausal women), Neoadjuvant letrozole (postmenopausal women), Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone), Neoadjuvant docetaxel + cyclophosphamide, Neoadjuvant docetaxel, Neoadjuvant docetaxel + trastuzumab + pertuzumab, Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab, Neoadjuvant olaparib, Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone), Breast conserving surgery or mastectomy + SNB/axillary dissection, Postoperative radiotherapy breast/chest wall + regional lymph nodes, Adjuvant trastuzumab, Adjuvant letrozole (postmenopausal women), Adjuvant tamoxifen + goserelin (premenopausal women), Adjuvant palbociclib (if palbociclib given neoadjuvant), Adjuvant Epirubicin+ Cyclophosphamide
Haukeland University Hospital, Helse Vest, Pfizer, AstraZeneca
Breast Cancer
06/20
06/30
PH002-TP-II, NCT03272477 / 2016-005157-21: Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients

Completed
2
257
Europe
Perjeta Injectable Product, Pertuzumab, Herceptin, Trastuzumab, Tamoxifen, Paclitaxel, Epirubicin, Cyclophosphamide, Anastrozole, Letrozole, Exemestane, Leuprorelin acetate, Goserelin, Leuporelin acetate, Biopsy, Surgery
Palleos Healthcare GmbH, Roche Pharma AG, WSG WOMEN´S HEALTHCARE STUDY GROUP, Cankado GmbH
Breast Neoplasms
07/20
03/24
NCT04676997: Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)

Recruiting
2
20
RoW
Camrelizumab, Nab paclitaxel, Epirubicin, Cyclophosphamide
Shandong Cancer Hospital and Institute, Jiangsu HengRui Medicine Co., Ltd.
Triple Negative Breast Cancer
07/21
02/24
2018-004457-24: PREDIX II HER2 - improving preoperative treatment of HER2 amplified breast cancer

Not yet recruiting
2
190
Europe
Herceptin, Tecentriq, Kadcyla, Docetaxel, Carboplatin, Epirubicin, Cyclophosphamide, Pertuzumab, Paklitaxel, Solution for injection, Solution for infusion, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Powder for solution for injection/infusion, Herceptin, Tecentriq, Kadcyla
Karolinska University Hospital, Karolinska University Hospital
Primary breast cancer, Newly diagnosed HER2 amplified breast cancer, Diseases [C] - Cancer [C04]
 
 
TREND, ChiCTR2000035262: Neoadjuvant Phase II Study of Tislelizumab combined with chemotherapy in Triple Negative Breast Cancer

Not yet recruiting
2
65
China
Tislelizumab
Liaoning Province Cancer Hospital ; Liaoning Province Cancer Hospital, BeiGene Shenzhou (Beijing) Biotechnology Co., Ltd.
Breast cancer
 
 
NCT01210768: A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients

Active, not recruiting
2
254
RoW
Epirubicin+Cyclophosphamide, liposomal-doxorubicin+Cyclophosphamide
TTY Biopharm
Breast Cancer
10/22
10/22
2019-002364-27: A study to assess atezolizumab in combination with dual HER2 blockade plus epirubicin as neoadjuvant therapy for HER2-positive early breast cancer

Not yet recruiting
2
58
Europe
Atezolizumab, Pertuzumab, Herceptin, RO5541267/F03, RO4368451, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Tecentriq, Perjeta, Herceptin
ABCSG (Austrian Breast & Colorectal Cancer Study Group), Roche Austria GmbH
HER2-positive early breast cancer, Early diagnosed with breast cancer that is HER2-positive, Diseases [C] - Cancer [C04]
 
 
SAFIR02_Breast, NCT02299999: - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Active, not recruiting
2
1460
Europe
AZD2014, AZD4547, AZD5363, AZD8931, Selumetinib, ARRY-142866, Vandetanib, CAPRELSA, Bicalutamide, Casodex, Olaparib, Lynparza, Anthracyclines, Doxorubicin, Epirubicin, liposomal doxorubicin, Taxanes, paclitaxel, docetaxel, cyclophosphamide, Novatrex, Imeth, DNA intercalators, capecitabine, 5-FU, gemcitabine, Methotrexate, vinca alkaloids, vinorelbine, vinblastine, vincristine, Platinum based chemotherapies, Platinum, carboplatin, cisplatin, Bevacizumab, Avastin, Mitomycin C, Ametycine, Eribulin, Halaven, MEDI4736
UNICANCER, Fondation ARC, AstraZeneca
Metastatic Breast Cancer
12/22
12/24
NCT04398914: Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Active, not recruiting
2
216
RoW
Pyrotinib, Trastuzumab, Pertuzumab, Nab-paclitaxel, EC chemotherapy, Physician's choice, T-DM1, Surgery
Shanghai Jiao Tong University School of Medicine, Jiangsu HengRui Medicine Co., Ltd.
Breast Cancer Invasive
12/22
12/27
PILHLE-001, NCT05165225: Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

Active, not recruiting
2
48
RoW
Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Jiangsu HengRui Medicine Co., Ltd.
Breast Cancer, HER2-low-expressing Breast Cancer, Hormone Receptor-positive Breast Cancer, Neoadjuvant Therapy
09/23
03/28
NCT06227117: Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

Recruiting
2
120
RoW
Disitamab Vedotin Injection （18 weeks）, DV,RC48-ADC, Toripalimab （18weeks）, JS001, Carboplatin, Disitamab Vedotin Injection （12 weeks）, Sequential Epirubicin, Epirubicin, Sequential CTX, CTX, cyclophosphamide, Toripalimab （12weeks）
RemeGen Co., Ltd.
Breast Cancer
12/25
12/26
neoMono, NCT04770272 / 2020-001651-40: Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy

Active, not recruiting
2
416
Europe
Atezolizumab 840 MG in 14 ML Injection, Tecentriq, Atezolizumab 1200 MG in 20 ML Injection, Carboplatin, Paclitaxel, Epirubicin, Cyclophosphamide, Biopsy Arm A, Biopsy Arm B, Surgery
Palleos Healthcare GmbH, Roche Pharma AG, Phaon Scientific GmbH, University Hospital, Essen, University Hospital Erlangen
Triple-negative Breast Cancer
07/23
08/24
2018-000406-36: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled phase-2-study (VESTIGE)

Not yet recruiting
2
240
Europe
nivolumab, ipilimumab, CISPLATIN, CAPECITABINE, Fluorouracil, EPIRUBICIN, Oxaliplatin, LEUCOVORIN, Docetaxel, L01XC11, Concentrate for solution for infusion, Film-coated tablet, Opdivo, Yervoy
European Organisation for Research and Treatment of Cancer (EORTC), European Organisation for the Research and Treatment of Cancer, BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
Gastric, lower esophageal or GE-junction adenocarcinoma, Stomach cancer and cancer of the lower part of the esophageus, Diseases [C] - Cancer [C04]
 
 
NCT04872985: Pyrotinib in Combination With Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: A Phase II Trial

Recruiting
2
140
RoW
Pyrotinib, Epirubicin, E, Doxorubicin Hydrochloride Liposome Injection, A, Cyclophosphamide, C, Docetaxel, T, Nab paclitaxel, Placebo
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Jiangsu HengRui Medicine Co., Ltd.
Breast Cancer, Hormone-receptor Positive Breast Cancer
12/23
12/28
NCT05447702: Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Recruiting
2
35
RoW
Camrelizumab, Apatinib, Nab-paclitaxel, Epirubicin, Cyclophosphamide
West China Hospital, Jiangsu HengRui Medicine Co., Ltd.
Triple Negative Breast Cancer
12/23
12/26
NCT06389006: To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

Recruiting
2
79
RoW
Disitamab Vedotin for Injection, RC48, Toripalimab, JS001, Epirubicin, Cyclophosphamide, CTX
RemeGen Co., Ltd.
Breast Cancer
06/25
12/26
VALENTINE, NCT05569811: NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - Trial

Active, not recruiting
2
120
Europe
Patritumab deruxtecan, Chemotherapy, Letrozole
SOLTI Breast Cancer Research Group, Daiichi Sankyo, Inc.
Breast Cancer
03/25
07/30
NCT05834582: Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer

Recruiting
2
60
RoW
Fluzoparib+Paclitaxel, Epirubicin+Cyclophosphamide
The First Affiliated Hospital with Nanjing Medical University, Jiangsu HengRui Medicine Co., Ltd.
TNBC - Triple-Negative Breast Cancer
06/25
06/26
EORTC 1745-ETF-BCG, NCT03609047 / 2018-002553-30: Adjuvant Palbociclib in Elderly Patients With Breast Cancer

Active, not recruiting
2
366
Europe, RoW
Palbociclib, Docetaxel / cyclophosphamide, doxorubicin/cyclophosphamide, epirubicin/cyclophosphamide, paclitaxel
European Organisation for Research and Treatment of Cancer - EORTC, Pfizer, Swedish Association of Breast Oncologists, ETOP IBCSG Partners Foundation, German Adjuvant Breast Cancer Group, SOLTI Breast Cancer Research Group, UNICANCER, Gruppo Oncologico Italiano di Ricerca Clinica, Breast International Group
Breast Cancer Stage II, Breast Cancer Stage III
06/26
09/32

Download Options